ENOV logo

Enovis Corporation Stock Price

NYSE:ENOV Community·US$1.2b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 10 Fair Values set on narratives written by author

ENOV Share Price Performance

US$21.69
-16.52 (-43.23%)
US$45.18
Fair Value
US$21.69
-16.52 (-43.23%)
52.0% undervalued intrinsic discount
US$45.18
Fair Value
Price US$21.69
AnalystConsensusTarget US$45.18
AnalystLowTarget US$33.00
AnalystHighTarget US$58.00

ENOV Community Narratives

AnalystConsensusTarget·
Fair Value US$45.18 52.0% undervalued intrinsic discount

Next Generation Orthopedic Technology Will Transform Global Care

0users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
AnalystLowTarget·
Fair Value US$33 34.3% undervalued intrinsic discount

Delayed Launches And Integration Risks Will Restrain Orthopedics Despite Demand

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AnalystHighTarget·
Fair Value US$58 62.6% undervalued intrinsic discount

Recon And Enabling Technologies Will Drive Significant Long Term Upside Potential

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$58
62.6% undervalued intrinsic discount
Profit Margin
14.34%
Future PE
11.52x
Price in 2028
US$76.8

Trending Discussion

Updated Narratives

ENOV logo

ENOV: Future Returns Will Likely Benefit From FY26 Cash Flow Execution

Fair Value: US$45.18 52.0% undervalued intrinsic discount
4 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
ENOV logo

Recon And Enabling Technologies Will Drive Significant Long Term Upside Potential

Fair Value: US$58 62.6% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
ENOV logo

Delayed Launches And Integration Risks Will Restrain Orthopedics Despite Demand

Fair Value: US$33 34.3% undervalued intrinsic discount
0 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Very undervalued with moderate growth potential.

0 Risks
4 Rewards

Enovis Corporation Key Details

US$2.2b

Revenue

US$879.3m

Cost of Revenue

US$1.4b

Gross Profit

US$2.6b

Other Expenses

-US$1.2b

Earnings

Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
-20.66
60.89%
-52.60%
86.9%
View Full Analysis

About ENOV

Founded
1995
Employees
7802
CEO
Damien McDonald
WebsiteView website
www.enovis.com

Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments. The Prevention and Recovery segment offers rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, electrical stimulators for pain management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals to treat patients with musculoskeletal conditions. The Reconstructive segment develops, manufactures, markets, and distributes surgical solutions that restore mobility and improve patient outcomes, which includes a range of differentiated implants, instrumentation, and enabling technologies used in elective and non-elective joint replacement, limb reconstruction, and foot and ankle procedures; and products for the hip, knee, shoulder, elbow, extremity reconstruction and fixation, foot, ankle, and finger, as well as surgical productivity tools. It also manufactures and distributes a range of products which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company distributes its products through independent distributors, direct salespeople, and patients. The company was formerly known as Colfax Corporation. Enovis Corporation was founded in 1995 and is headquartered in Wilmington, Delaware.

Recent ENOV News & Updates

Recent updates

No updates